Author

Chenglong Han 1

1 Janssen R&D, LLC,Spring House,United States

EARLY PRO-2 SYMPTOM REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

William J. Sandborn, Tadakazu Hisamatsu, Kathleen Weisel, Susana Gonzalez, Mary Ellen Frustaci, Zijiang Yang, Jewel Johanns, Matthew Germinaro, Brian Feagan, Aniita Afzali, Walter Reinisch, Jane Andrews, Omoniyi J. Adedokun, Chenglong Han

PATIENT-REPORTED OUTCOMES CAN BE USED TO MONITOR CONTINUOUS CLINICAL RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH GOLIMUMAB: RESULTS FROM THE PURSUIT MAINTENANCE STUDY

Walter Reinisch, Jean-Frederic Colombel, Brian G. Feagan, Chenglong Han, Colleen W. Marano, Richard S Strauss, Peter R. Gibson, William Sandborn, Susan Huyck, Freddy Cornillie, Paul Rutgeerts

PATIENT-REPORTED OUTCOMES OF RESPONSE AND REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT AS MEASURED BY THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

Remo Panaccione, Geert R. D'Haens, Kathleen Weisel, Susana Gonzalez, Mary Elleen Frustaci, Zijiang Yang, Jewel Johanns, Matthew Germinaro, Bruce E. Sands, David T. Rubin, Chenglong Han, Julian Panés, Silvio Danese

Ustekinumab Improved Work Productivity in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 UNIFI Induction and Maintenance Studies

Dominik Naessens, Chenglong Han, Hongyan Zhang, Jewel Johanns, Colleen W. Marano, Bruce E. Sands

USTEKINUMAB IMPROVES PRODUCTIVITY AND REDUCES WORK LIMITATION OF PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THREE PHASE 3 CLINICAL TRIALS

Bruce E. Sands, Chenglong Han, Dominik Naessens, Christopher Gasink, Douglas Jacobstein, L.L. Gao, Brian G. Feagan

Item 1 - 5 / 5
1